Compensated Awareness Post View
Disclaimer
Cytori Therapeutics, Inc. (CYTX) Establishing Early Presence in Emerging Field of Regenerative Medicine
Cytori Therapeutics, Inc. is a biotechnology company developing autologous cell therapies from adipose connective tissue designed to treat a variety of medical conditions. Since 2001, the company has leveraged its exploration of the massive treatment potential of adult adipose-derived stem and regenerative cells to position itself as a global leader in the emerging field of regenerative medicine. By utilizing a patient’s own adipose tissue, Cytori eliminates the necessity for offsite cell growth operations while effectively minimizing common transplant risks, including autoimmune rejection.
The company’s current cell therapy pipeline includes three drug candidates in six unique indications across two countries and the European Union. Cytori’s leading candidate, ECCS-50, is currently approved in the United States and Europe to begin a phase III clinical trial for the treatment of scleroderma hand dysfunction.
According to the National Institute of Health, scleroderma is a group of diseases that affect connective tissue in the body, potentially causing swelling or pain in the muscles and joints. Despite affecting as many as 100,000 people in the United States, there is currently no drug that has been clearly proven to stop, or reverse, the disease’s key symptoms. For Cytori, this unmet need should clear the way for favorable results upon the eventual commercialization of ECCS-50.
From a financial standpoint, Cytori took major steps in the first quarter of 2015 toward continued development and testing of its promising product pipeline. The company’s operating cash burn was reduced by over 44 percent in the period and overall contract revenue rose by 350 percent, as compared to the first quarter of 2014, providing prospective investors with a preview of the Cytori’s growth potential moving forward.
“We accomplished the key objectives we hoped to achieve over the past four quarters and are off to a good start in 2015,” Dr. Marc H. Hendrick, president and chief executive officer of Cytori, stated in a news release. “Now the lion’s share of our corporate focus and energy will go into trial enrollment and strategically managing our clinical pipeline.”
In June, the company made progress toward this objective through the completion of enrollment for its impending phase IIb clinical trial, which will study the safety, feasibility and dosing intraarticular administration of Cytori’s ECCO-50 cellular therapeutic in patients with knee osteoarthritis. Look for the company to build on this progress in the months to come as it prepares for its pivotal phase III trial of ECCS-50.
For more information, visit www.cytori.com
